# Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

> **NCT07243470** · PHASE1,PHASE2 · RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 70 (estimated)

## Conditions studied

- Glioma
- CNS Tumor, Adult
- CNS Tumor, Childhood

## Interventions

- **DRUG:** Tarlatamab
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT07243470
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2029-10
- **Final completion:** 2030-10
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243470, "Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07243470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*